Curcumin supplementation markedly reduces ALT and AST levels in NAFLD patients but shows no overall effect on ALP, except with longer supplementation.
According to the findings of a study, curcumin, a powerful antioxidant, may help improve liver health in patients with nonalcoholic fatty liver disease (NAFLD). This systematic review and meta-analysis investigated the effect of curcumin supplementation on liver enzymes in NAFLD patients, specifically alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP).
Relevant randomized clinical trials (RCTs) were procured from the Web of Science, SCOPUS, and PubMed databases. A random-effects model measured pooled effect sizes via weighted mean differences (WMDs) and 95% confidence intervals (CIs). The pooled meta-analysis indicated a prominent reduction in ALT (WMD: –8.72) and AST (WMD: –6.35) levels following curcumin use. However, the pooled analysis of 5 trials revealed no vital association between curcumin therapy and ALP levels (WMD: –4.71).
Nevertheless, subgroup analysis exhibited significant effects of curcumin on ALP when supplementation duration was longer. With NAFLD becoming a growing global health concern, these findings support curcumin’s potential role in liver health. However, experts call for further large-scale, high-quality trials to substantiate these effects and establish optimal dosing strategies.
Food Science & Nutrition
Therapeutic effects of curcumin supplementation on liver enzymes of nonalcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials
Armin Ebrahimzadeh et al.
Comments (0)